Claims for Patent: 7,338,968

Summary for Patent: 7,338,968

Title:	Thiadiazoles AS CXC- and CC- chemokine receptor ligands
Abstract:	Disclosed are novel compounds of the formula: ##STR00001## and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and ischemia reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.
Inventor(s):	Biju; Purakkattle J. (Scotch Plains, NJ), Taveras; Arthur G. (Southborough, MA), Merritt; J. Robert (Ewing, NJ), Baldwin; John J. (Gwynedd Valley, PA), Yu; Younong (East Brunswick, NJ), Zheng; Junying (Bridgewater, NJ), Chao; Jianhua (Pompton Lakes, NJ), Aki; Cynthia J. (Livingston, NJ)
Assignee:	Schering Corporation (Kenilworth, NJ)
Application Number:	11/013,753
Patent Claims:	1. A compound of the formula: ##STR02755## and the pharmaceutically acceptable salts thereof, wherein: A is selected from the group consisting of: ##STR02756## ##STR02757## ##STR02758## wherein the above rings of said A groups are substituted with 1 to 6 substituents each independently selected from the group consisting of: R.sup.9 groups; ##STR02759## wherein one or both of the above rings of said A groups are substituted with 1 to 6 substituents each independently selected from the group consisting of: R.sup.9 groups; and ##STR02760## B is selected from the group consisting of ##STR02761## n is 0; R.sup.2 is selected from the group consisting of: hydrogen, OH, --C(O)OH, --SH, --SO.sub.2NR.sup.13R.sup.14, --NHC(O)R.sup.13, --NHSO.sub.2NR.sup.13R.sup.14, --NHSO.sub.2R.sup.13, --NR.sup.13R.sup.14 , --C(O)NHOR.sup.13, --C(O)NR.sup.13OH, --S(O.sub.2)OH, and --OC(O)R.sup.13; each R.sup.3 and R.sup.4 is independently selected from the group consisting of: hydrogen, cyano, halogen, alkyl, alkoxy, cycloalkyl substituted with 1 to 4 alkyl groups wherein each alkyl group is independently selected, unsubstituted cycloalkyl, cycloalkyl substituted with 1 to 4 alkyl groups, --OH, --CF.sub.3, --OCF.sub.3, --NO.sub.2, --C(O)R.sup.13, --C(O)OR.sup.13, --C(O)NHR.sup.17, --C(O)NR.sup.13R.sup.14, --SO.sub.(t)NR.sup.13R.sup.14, --SO.sub.(t)R.sup.13, --C(O)NR.sup.13OR.sup.14, unsubstituted or substituted aryl, ##STR02762## wherein there are 1 to 6 substituents on said substituted aryl group and each substituent is independently selected from the group consisting of: R.sup.9 groups; each R.sup.5 and R.sup.6 are the same or different and are independently selected from the group consisting of hydrogen, halogen, alkyl, alkoxy, --CF.sub.3, --OCF.sub.3, --NO.sub.2, --C(O)R.sup.13--C(O)OR.sup.13, --C(O)NR.sup.13R.sup.14, --SO.sub.(t)NR.sup.13R.sup.14, --C(O) NR.sup.13OR.sup.14, cyano, and unsubstituted aryl; each R.sup.7 and R.sup.8 is independently selected from the group consisting of: H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heteroarylalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkylalkyl, --CO.sub.2R.sup.13, --CONR.sup.13R.sup.14, alkynyl, alkenyl, and cycloalkenyl; and wherein there are one or more substituents on said substituted R.sup.7 and R.sup.8 groups, wherein each substitutent is independently selected from the group consisting of: a) halogen, b) --CF.sub.3, c)--COR.sup.13, d) --OR.sup.13, e) --NR.sup.13R.sup.14, f) --NO.sub.2, g) --CN, h) --SO.sub.2OR.sup.13, i) --CO.sub.2R.sup.13, j) --C(O)NR.sup.13R.sup.14, k) --SO.sub.2NR.sup.13R.sup.14, l) --SO.sub.2R.sup.13, m) --OC(O)R.sup.13, n) --OC(O)NR.sup.13R.sup.14, o) --NR.sup.13C(O)R.sup.14, and p) --NR.sup.13CO.sub.2R.sup.14; each R.sup.9 is independently selected from the group consisting of: a) --R.sup.13, R.sup.12 is selected from the group consisting of: hydrogen, --C(O)OR.sup.13, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted alkyl, unsubstituted or substituted cycloalkylalkyl, and unsubstituted or substituted heteroarylalkyl group; wherein there are 1 to 6 substituents on the substituted R.sup.12 groups and each substituent is independently selected from the group consisting of: R.sup.9 groups; each R.sup.13 and R.sup.14 is independently selected from the group consisting of: H, and unsubstituted alkyl; each R.sup.15 is independently selected from the group consisting of: H, alkyl, aryl, arylalkyl, cycloalkyl and heteroaryl; R.sup.17 is selected from the group consisting of: --SO.sub.2alkyl, --SO.sub.2aryl, --SO.sub.2cycloalkyl, and --SO.sub.2heteroaryl; R.sup.30 is selected from the group consisting of: alkyl, cycloalkyl, --CN, --NO.sub.2, or --SO.sub.2R.sup.15 provided that R.sup.15 is not H; and t is 0, 1 or 2. 2. The compound of claim 1 wherein A is selected from the group consisting of: ##STR02763## 3. The compound of claim 1 wherein substituent A is: ##STR02764## wherein the furan ring is unsubstituted or substituted with 1 or 2 alkyl groups wherein each alkyl group is independently selected, R.sup.7 is selected from the group consisting of: --CF.sub.3, alkyl and cycloalkyl, and R.sup.8 is H. 4. The compound of claim 1 wherein substituent A is: ##STR02765## wherein the furan ring is substituted with 1 or 2 alkyl groups independently selected from the group consisting of methyl, ethyl and isopropyl, R.sup.7 is selected from the group consisting of: ethyl, isopropyl and t-butyl, and R.sup.8 is H. 5. The compound of claim 1 wherein A is selected from the group consisting of: ##STR02766## ##STR02767## ##STR02768## 6. The compound of claim 1 wherein A is selected from the group consisting of: ##STR02769## 7. The compound of claim 1 wherein substituent A is selected from the group consisting of: ##STR02770## 8. The compound of claim 1 wherein B is selected from the group consisting of: ##STR02771## 9. The compound of claim 1 wherein B is selected from the group consisting of: ##STR02772## 10. The compound of claim 1 wherein B is selected from the group consisting of: ##STR02773## 11. The compound of claim 1 wherein B is ##STR02774## 12. The compound of claim 1 wherein B is: ##STR02775## wherein R.sup.2 is --OH. 13. The compound of claim 1 wherein B is: ##STR02776## wherein R.sup.2 is --OH, and R.sup.13 and R.sup.14 are independently selected from the group consisting of H and alkyl. 14. The compound of claim 1 wherein: (1) substituent A in formula IA is selected from the group consisting of: ##STR02777## wherein the above rings are unsubstituted, or the above rings are substituted with 1 to 3 substituents independently selected from the group consisting of: F, Cl, Br, alkyl, cycloalkyl, and --CF.sub.3; R.sup.7 is selected from the group consisting of: H, --CF.sub.3, --CF.sub.2CH.sub.3, methyl, ethyl, isopropyl, cyclopropyl and t-butyl; and R.sup.8 is H; and (2) substituent B in formula IA is selected from the group consisting of: ##STR02778## wherein: R.sup.2 is selected from the group consisting of: H, OH, --NHC(O)R.sup.13 and --NHSO.sub.2R.sup.13; R.sup.3 is selected from the group consisting of: --C(O)NR.sup.13R.sup.14--SO.sub.2NR.sup.13R.sup.14, --NO.sub.2, cyano, and --SO.sub.2R.sub.13; R.sup.4 is selected from the group consisting of: H, --NO.sub.2, cyano, alkyl, halogen and --CF.sub.3; R.sub.5 is selected from the group consisting of: H, --CF.sub.3, --NO.sub.2, halogen and cyano; R.sup.6 is selected from the group consisting of: H, alkyl and --CF.sub.3; and R.sup.11 is selected from the group consisting of: H, halogen and alkyl. 15. The compound of claim 1 wherein: (1) substituent A in formula IA is selected from the group consisting of: ##STR02779## (2) substituent B in formula IA is selected from the group consisting of: ##STR02780## wherein: R.sup.2 is --OH; R.sup.3 is selected from the group consisting of: --SO.sub.2NR.sup.13R.sup.14 and --CONR.sup.13R.sup.14; R.sup.4 is selected form the group consisting of: H, Br, --CH.sub.3, ethyl and --CF.sub.3; R.sup.5 is selected from the group consisting of: H and cyano; R.sup.6 is selected from the group consisting of: H, --CH.sub.3 and --CF.sub.3; R.sup.11 is H; and R.sup.13 and R.sup.14 are independently selected from the group consisting of H and methyl. 16. The compound of claim 1 wherein substituent A is selected from the group consisting of: ##STR02781## and substituent B is selected from the group consisting of: ##STR02782## 17. The compound of claim 1 wherein substituent A is selected from the group consisting of: ##STR02783## and substituent B is selected from the group consisting of: ##STR02784## 18. A pharmaceutically acceptable salt of a compound of claim 1. 19. A sodium salt of a compound of claim 1. 20. A calcium salt of a compound of claim 1. 21. The compound of claim 1 selected from the group consisting of ##STR02785## ##STR02786## ##STR02787## ##STR02788## ##STR02789## ##STR02790## ##STR02791## ##STR02792## ##STR02793## ##STR02794## ##STR02795## ##STR02796## ##STR02797## ##STR02798## ##STR02799## ##STR02800## ##STR02801## and the pharmaceutically acceptable salts thereof. 22. The compound of claim 1 selected from the group consisting of ##STR02802## ##STR02803## ##STR02804## ##STR02805## ##STR02806## ##STR02807## ##STR02808## ##STR02809## and the pharmaceutically acceptable salts thereof. 23. The compound of claim 1 selected from the group consisting of ##STR02810## ##STR02811## ##STR02812## ##STR02813## ##STR02814## ##STR02815## ##STR02816## ##STR02817## and the pharmaceutically acceptable salts thereof. 24. The compound of claim 1 selected from the group consisting of ##STR02818## ##STR02819## ##STR02820## ##STR02821## ##STR02822## ##STR02823## and the pharmaceutically acceptable salts thereof. 25. The compound of claim 1 wherein said compound is ##STR02824## or a pharmaceutically acceptable salt thereof. 26. The compound of claim 1 wherein said compound is ##STR02825## or a pharmaceutically acceptable salt thereof. 27. The compound of claim 1 wherein said compound is ##STR02826## or a pharmaceutically acceptable salt thereof. 28. The compound of claim 1 wherein said compound is ##STR02827## or a pharmaceutically acceptable salt thereof. 29. The compound of claim 1 wherein said compound is ##STR02828## or a pharmaceutically acceptable salt thereof. 30. The compound of claim 1 wherein said compound is ##STR02829## or a pharmaceutically acceptable salt thereof. 31. The compound of claim 1 wherein said compound is ##STR02830## or a pharmaceutically acceptable salt thereof. 32. The compound of claim 1 wherein said compound is ##STR02831## or a pharmaceutically acceptable salt thereof. 33. The compound of claim 1 in isolated and pure form. 34. A pharmaceutical composition comprising at least one compound of claim 1, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier. 35. A pharmaceutical composition comprising at least one compound of claim 1, or a pharmaceutically acceptable salt thereof, and at least one anticancer agent selected from the group consisting of: (a) microtubule affecting agents, (b) antineoplastic agents, (c) anti-angiogenesis agents, (d) VEGF receptor kinase inhibitors, (e) antibodies against the VEGF receptor, and (f) interferon, and a pharmaceutically acceptable carrier. 36. A pharmaceutical composition comprising at least one compound of claim 1, or a pharmaceutically acceptable salt thereof, and at least one antineoplastic agent selected from the group consisting of: gemcitabine, paclitaxel, 5-Fluorourcil, cyclophosphamide, temozolomide, and Vincristine, and a pharmaceutically acceptable carrier. 37. A pharmaceutical composition comprising at least one compound of claim 1, or a pharmaceutically acceptable salt thereof, and a microtubule affecting agent, and a pharmaceutically acceptable carrier. 38. A pharmaceutical composition comprising at least one compound of claim 1, or a pharmaceutically acceptable salt thereof, at least one other medicament selected from the group consisting of: a) disease modifying antirheumatic drugs; b) nonsteroidal anitinflammatory drugs; c) COX-2 selective inhibitors; d) COX-1 inhibitors; e) immunosuppressives; and f) steroids; and a pharmaceutically acceptable carrier. 39. A pharmaceutical composition comprising at least one compound of claim 1, or a pharmaceutically acceptable salt thereof, at least one compound selected from the group consisting of: glucocorticoids, 5-lipoxygenase inhibitors, .beta.-2 adrenoceptor agonists, muscarinic M1 antagonists, muscarinic M3 antagonists, muscarinic M2 agonists, NK3 antagonists, LTB4 antagonists, cysteinyl leukotriene antagonists, bronchodilators, PDE4 inhibitors, PDE inhibitors, elastase inhibitors, MMP inhibitors, phospholipase A2 inhibitors, phospholipase D inhibitors, histamine H1 antagonists, histamine H3 antagonists, dopamine agonists, adenosine A2 agonists, NKI and NK2 antagonists, GABA-b agonists, nociceptin agonists, expectorants, mucolytic agents, decongestants, antioxidants, anti-IL-8 anti-bodies, anti-IL-5 antibodies, anti-IgE antibodies, anti-TNF antibodies, IL-10, adhesion molecule inhibitors, and growth hormones,. and a pharmaceutically acceptable carrier. 40. A pharmaceutical composition comprising at least one compound of claim 1, or a pharmaceutically acceptable salt thereof, at least one compound selected from the group consisting of: glatiramer acetate, glucocorticoids, methotrexate, azothioprine, mitoxantrone, chemokine inhibitors, and CB2-selective agents, and a pharmaceutically acceptable carrier. 41. A pharmaceutical composition comprising at least one compound of claim 1, or a pharmaceutically acceptable salt thereof, at least one compound selected from the group consisting of: methotrexate, cyclosporin, leflunimide, sulfasalazine, .beta.-methasone, .beta.-interferon, glatiramer acetate, and prednisone, and a pharmaceutically acceptable carrier. 42. A pharmaceutical composition comprising at least one compound of claim 1, or a pharmaceutically acceptable salt thereof, at least one compound selected from the group consisting of: COX-2 inhibitors, COX inhibitors, immunosuppressives (e.g., methotrexate, cyclosporin, leflunimide and sulfasalazine), steroids (e.g., betamethasone, cortisone and dexamethasone), PDE IV inhibitors, anti-TNF-.alpha. compounds, MMP inhibitors, glucocorticoids, chemokine inhibitors, and CB2-selective inhibitors, and a pharmaceutically acceptable carrier. 43. A pharmaceutical composition comprising at least one compound of claim 1, or a pharmaceutically acceptable salt thereof, at least one compound selected from the group consisting of: thrombolitics, antiplatelet agents, abciximab eftiifbatide, and anticoagulants, and a pharmaceutically acceptable carrier. 44. A pharmaceutical composition comprising at least one compound of claim 1, or a pharmaceutically acceptable salt thereof, at least one compound selected from the group consisting of: tenecteplase, TPA, alteplase, abciximab, eftiifbatide, and heparin, and a pharmaceutically acceptable carrier. 45. A pharmaceutical composition comprising at least one compound of claim 1, or a pharmaceutically acceptable salt thereof, at least one compound selected from the group consisting of: immunosuppressives, steroids and anti-TNF-.alpha. compounds, and a pharmaceutically acceptable carrier. 46. A pharmaceutical composition comprising at least one compound of claim 1, or a pharmaceutically acceptable salt thereof, at least one medicament selected from the group consisting of: NSAIDs, COXIB inhibitors, anti-depressants, and anti-convulsants, and a pharmaceutically acceptable carrier.

Details for Patent 7,338,968

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	ACTIVASE	alteplase	For Injection	103172	11/13/1987		2023-12-19
Genentech, Inc.	CATHFLO ACTIVASE	alteplase	For Injection	103172	09/04/2001		2023-12-19
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575	12/22/1994		2023-12-19
Jubilant Hollisterstier Llc	N/A	positive skin test control-histamine	Injection	103891	03/13/1924		2023-12-19